Monday, June 1, 2026, Chicago, Illinois, 7:00 PM – 9:00 PM Central Time (8:00 PM – 10:00 PM Eastern Time)
What Clinicians Want to Know: Addressing Community Oncologists’ Questions About the Current and Future Role of Antibody-Drug Conjugates in the Management of Breast Cancer
A CME Symposium Held Adjunct with the 2026 ASCO® Annual Meeting
Location
Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois
Phone: (312) 922-4400
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting
Meeting Room
Continental Room A (Lobby Level)
No registration fee is charged for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.
Faculty Erika Hamilton, MD
Chief Development Officer, Late Phase
Director, Breast Cancer Research Program
Sarah Cannon Research Institute
SCRI Oncology Partners
Nashville, Tennessee
Nadia Harbeck, MD, PhD
Breast Center Director
Department of Obstetrics and Gynecology
and Comprehensive Cancer Center Munich
LMU University Hospital
Munich, Germany
Additional faculty to be announced.
Moderator Hope S Rugo, MD
Director, Women’s Cancers Program
Division Chief, Breast Medical Oncology
Professor, Department of Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California
Professor Emeritus, UCSF
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.
Not an official event of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting
MODULE 1: Evolving Role of Antibody-Drug Conjugates (ADCs) in the Management of Metastatic Triple-Negative Breast Cancer (mTNBC)
Scientific rationale for investigating TROP2-directed ADCs for previously untreated mTNBC
Key efficacy and safety data from the Phase III ASCENT-04/KEYNOTE-D19 and ASCENT-03 trials evaluating sacituzumab govitecan in combination with pembrolizumab and as monotherapy for patients with previously untreated PD-L1-positive and PD-L1-negative mTNBC, respectively
Recently published data from the Phase III TROPION-Breast02 study of first-line datopotamab deruxtecan (Dato-DXd) versus chemotherapy for patients with advanced TNBC for whom immunotherapy was not an option
Potential roles of sacituzumab govitecan and Dato-DXd for previously untreated mTNBC
Updated data with trastuzumab deruxtecan (T-DXd) in the subset of patients with previously treated hormone receptor (HR)-negative, HER2-low advanced breast cancer in the Phase III DESTINY-Breast04 study; current role alongside other treatment options
Clinical trial findings with and ongoing investigation of other ADCs for mTNBC, such as sacituzumab tirumotecan and izalontamab brengitecan
MODULE 2: Integrating ADCs into the Management of HER2-Positive Metastatic Breast Cancer (mBC)
Historical outcomes with standard HER2-targeted therapies for newly diagnosed HER2-positive mBC; rationale for the evaluation of HER2-targeted ADCs in the front-line setting
Published efficacy and safety findings from the Phase III DESTINY-Breast09 trial documenting the benefit of T-DXd/pertuzumab versus taxane/trastuzumab/pertuzumab as first-line therapy for HER2-positive mBC
Implications of the DESTINY-Breast09 trial for sequencing therapies for HER2-positive mBC
Intracranial efficacy documented with T-DXd in published clinical trials, including DESTINY-Breast01, 02 and 03, DESTINY-Breast12, DEBBRAH and TUXEDO-1; implications for the management of HER2-positive mBC
Outcomes documented among patients with previously treated HER2-positive mBC without CNS involvement in pivotal clinical studies of T-DXd
Other promising HER2-directed ADCs under investigation for HER2-positive mBC
MODULE 3: Role of ADCs in the Management of Endocrine-Resistant HR-Positive mBC
Long-term efficacy and safety findings from the Phase III TROPiCS-02 trial of sacituzumab govitecan for previously treated HR-positive, HER2-negative mBC
Optimal integration of sacituzumab govitecan into management algorithms for HR-positive, HER2-negative disease
Available efficacy and safety findings from the Phase III TROPION-Breast01 study of Dato-DXd versus investigator’s choice of chemotherapy for pretreated HR-positive, HER2-negative mBC
FDA approval of Dato-DXd for patients with HR-positive, HER2-negative mBC who have previously received endocrine-based therapy and chemotherapy; current clinical role
Available data from the DESTINY-Breast04 and DESTINY-Breast06 studies evaluating T-DXd versus chemotherapy for patients with previously treated HER2-low and HER2-ultralow advanced breast cancer
FDA approval of T-DXd for advanced HR-positive, HER2-low and HER2-ultralow breast cancer progressing after one or more endocrine therapies in the metastatic setting; optimal incorporation into disease management
MODULE 4: Emerging Utility of ADCs for Localized Breast Cancer
Key clinical factors in the selection of neoadjuvant and adjuvant systemic therapy for patients with HER2-positive localized breast cancer; effect of various therapeutic approaches on outcomes
Published findings from the Phase III DESTINY-Breast11 study evaluating T-DXd as a component of neoadjuvant therapy for patients with high-risk, HER2-positive localized breast cancer
Recently presented data from the Phase III DESTINY-Breast05 study of T-DXd versus T-DM1 for patients with high-risk HER2-positive breast cancer and residual invasive disease after neoadjuvant therapy
Implications of the DESTINY-Breast11 and DESTINY-Breast05 studies for the management of HER2-positive localized breast cancer
Ongoing Phase III trials, such as ASCENT-05, ADAPT-TN-III, ADAPT-TN-IV, TROPION-Breast04, TROPION-Breast05, TroFuse-012 and TroFuse-032, evaluating TROP2 ADCs as a component of neoadjuvant or adjuvant therapy for localized disease; estimated completion dates
MODULE 5: Tolerability Considerations with ADCs for Breast Cancer
Spectrum, incidence and severity of common and unique adverse events (AEs) with different ADCs employed in the management of breast cancer
Monitoring and management of acute “chemotherapy-like” AEs reported with ADCs, such as cytopenias and gastrointestinal events
Recommended algorithms for mitigating more serious (eg, interstitial lung disease, left ventricular dysfunction) or unique (eg, oral mucositis/stomatitis, ocular AEs) toxicities documented with one or more ADCs
Strategies to distinguish the cause of AEs that could be attributable to either agent in ADC-containing combination regimens
Impact on tolerability, if any, of the placement of ADCs in the treatment course (eg, later-line therapy for metastatic disease, first-line therapy for metastatic disease or neoadjuvant/adjuvant therapy)
Target Audience
This activity is intended for medical and radiation oncologists, hematologists, hematology-oncology fellows, general and breast surgeons and other healthcare providers involved in the treatment of breast cancer.
Learning Objectives
To be announced.
CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.
FACULTY To be announced.
MODERATOR
To be announced.
EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400
Meeting Room
Continental Room A (Lobby Level)
Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.
This activity is intended for medical and radiation oncologists, hematologists, hematology-oncology fellows, general and breast surgeons and other healthcare providers involved in the treatment of breast cancer.
At this time in-person registration for this educational activity is limited to practicing clinicians actively caring for patients with cancer. For all other professionals, including industry personnel*, we are unable to confirm seating at this time. If you would like to stand by for participation in this event, please provide your contact information by choosing the second registration option below. Should seats become available for the program, we will notify you.
No fee is charged to attend the session virtually.
NOTICE: Registration for this event is independent of registration for the 2026 ASCO Annual Meeting.
IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.
STANDBY IN-PERSON Registration for other/industry professionals*
If you would like to stand by for participation in this event, please provide your contact information here. We will notify you if seats become available.
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.
Not an official event of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.
